US20130172737A1 - Absorbable sponge with contrasting agent - Google Patents
Absorbable sponge with contrasting agent Download PDFInfo
- Publication number
- US20130172737A1 US20130172737A1 US13/776,952 US201313776952A US2013172737A1 US 20130172737 A1 US20130172737 A1 US 20130172737A1 US 201313776952 A US201313776952 A US 201313776952A US 2013172737 A1 US2013172737 A1 US 2013172737A1
- Authority
- US
- United States
- Prior art keywords
- pledget
- biopsy
- adaptor
- needle
- sponge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 23
- 108010010803 Gelatin Proteins 0.000 claims description 16
- 229920000159 gelatin Polymers 0.000 claims description 16
- 239000008273 gelatin Substances 0.000 claims description 16
- 235000019322 gelatine Nutrition 0.000 claims description 16
- 235000011852 gelatine desserts Nutrition 0.000 claims description 16
- 239000006260 foam Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000001574 biopsy Methods 0.000 abstract description 97
- 206010052428 Wound Diseases 0.000 abstract description 5
- 238000002594 fluoroscopy Methods 0.000 abstract description 2
- 238000003384 imaging method Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 51
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 18
- 239000012530 fluid Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 230000023597 hemostasis Effects 0.000 description 10
- 210000000056 organ Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 9
- 230000000740 bleeding effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 239000002872 contrast media Substances 0.000 description 5
- 238000013188 needle biopsy Methods 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 241001631457 Cannula Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000013152 interventional procedure Methods 0.000 description 2
- 238000004898 kneading Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 206010053567 Coagulopathies Diseases 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 239000002257 antimetastatic agent Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006261 foam material Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960004647 iopamidol Drugs 0.000 description 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960000554 metrizamide Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- BPUBBGLMJRNUCC-UHFFFAOYSA-N oxygen(2-);tantalum(5+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Ta+5].[Ta+5] BPUBBGLMJRNUCC-UHFFFAOYSA-N 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WCIMWHNSWLLELS-UHFFFAOYSA-M sodium;3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoate Chemical compound [Na+].CNC(=O)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I WCIMWHNSWLLELS-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- -1 such as Substances 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- 229910001936 tantalum oxide Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/005—Devices for introducing or retaining media, e.g. remedies, in cavities of the body for contrast media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/02—Instruments for taking cell samples or for biopsy
- A61B10/0233—Pointed or sharp biopsy instruments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/485—Diagnostic techniques involving fluorescence X-ray imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/48—Diagnostic techniques
- A61B8/481—Diagnostic techniques involving the use of contrast agent, e.g. microbubbles introduced into the bloodstream
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00637—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect for sealing trocar wounds through abdominal wall
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/0057—Implements for plugging an opening in the wall of a hollow or tubular organ, e.g. for sealing a vessel puncture or closing a cardiac septal defect
- A61B2017/00646—Type of implements
- A61B2017/00654—Type of implements entirely comprised between the two sides of the opening
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
- A61B2090/3933—Liquid markers
Definitions
- the invention relates to an absorbable sponge, and more particularly, the invention relates to the delivery of a contrasting agent to a specific area or site in a mammal after a surgical or interventional procedure.
- the contrasting agent facilitates the location of the area or site even weeks or months after the initial procedure.
- Percutaneous needle biopsy of solid organs is one of the most common interventional medical procedures. Millions of percutaneous needle biopsies are performed annually in the United States and throughout the world. Percutaneous biopsy is a safe procedure which has supplanted surgical biopsy for many indications, such as biopsy and liver biopsy.
- Possible complications of needle biopsy include bleeding at the biopsy site.
- the amount of bleeding is related to a number of factors including needle size, tissue sample size, patient's coagulation status, and the location of the biopsy site.
- vascular organs such as the liver, a common biopsy target, may bleed significantly after needle biopsy.
- Sterile sponges such as GELFOAM
- GELFOAM Sterile sponges
- the sponge sheets are left in the surgical site after surgery to stop bleeding and are absorbed by the body.
- a number of techniques have used these absorbable sterile sponge materials to plug a biopsy tract to minimize or prevent bleeding.
- the absorbable sponge provides a mechanical blockage of the tract, encourages clotting, and minimizes bleeding though the biopsy tract.
- a mechanic clip device is often attached to the site where tissue is removed, so that if further treatment is later required the location of the site can be identified.
- the time period between the biopsy and treatment may be weeks during which time the clip may become dislodged thereby making it difficult to relocate the site.
- the present invention is based in part on the discovery that adding a contrasting agent (e.g, radiopaque agent) to an absorbable sponge provides for a material that not only facilitates hemostasis of a biopsy tract or other puncture wound but also permits precise identification of the site's location.
- a contrasting agent e.g, radiopaque agent
- the invention is directed to a method for marking a bodily site in a patient that includes the steps of:
- the exact location of the bodily site can be located many weeks or longer following positioning of the absorbable sponge material.
- the invention is directed to a method for performing a biopsy that included the steps of:
- the invention is directed to a liquid permeable, absorbable, gelatin sponge that is prepared by a process that includes the steps of:
- FIG. 1 is a side cross sectional view of an adaptor for delivery of a pledget to a needle
- FIG. 2 is a side cross sectional view of a syringe for connection to the adaptor
- FIG. 3 is a side cross sectional view of an adaptor and syringe combination with a pledget positioned within the adaptor;
- FIG. 4 is a side cross sectional view of the loaded adaptor and syringe combination in preparation for connection to a biopsy needle;
- FIG. 5 is a side cross sectional view of an alternative embodiment of an adaptor for delivery of a pledget including a template attached to the adaptor;
- FIG. 6 is a top view of the template as it is used for cutting a pledget from an absorbable sponge sheet
- FIG. 7 is a side cross sectional view of a portion of an organ and a system for delivering a pledget into a biopsy tract in the organ.
- the present invention is directed to an absorbable sponge material containing a contrasting agent.
- the absorbable sponge material is delivered to a specific area or site in a patient (i.e., mammal) after a surgical or interventional procedure.
- the sponge material can be placed in the biopsy tract or other puncture wound and the contrasting agent enables marking or identification of the area or site.
- the absorbable sponge will be described in connection with treatment of a biopsy tract after a percutaneous needle biopsy.
- the absorbable sponge material can also exhibit secondary benefits of, for example, facilitating hemostasis and delivering therapeutic agents.
- “Pledget” means a piece of absorbable sponge containing a contrasting agent preferably of a generally elongated shape having a size which allows injection in a hydrated state through a biopsy needle or other cannula.
- “Sponge” means a biocompatible material which is capable of being hydrated and is resiliently compressible in a hydrated state.
- the sponge is non-immunogenic and is absorbable.
- “Absorbable sponge” means a sponge which when implanted within a patient (i.e., human or other mammalian body) is absorbed by the body.
- the absorbable sponge contains a contrasting agent which may or may not be absorbable. Besides the contrasting agent, the sponge can also be used to deliver a beneficial agent such as thrombin, radiation treatment or the like.
- “Bodily site” means any tissue in a mammal where the absorbable sponge containing the contrasting agent can be introduced.
- the invention is particularly suited for introducing the absorbable sponge into tissue sites where further treatment may be required, for example, as in the case following biopsy.
- “Hydrate” means to partially or fully saturate with a fluid, such as, saline, water, or the like.
- “Kneading” of the absorbable sponge material means both dry and wet manipulation of the sponge material which compresses, enlarges, or changes the shape of the sponge material causing the sponge material to have improved expansion response.
- “Contrasting agent” means a biocompatible material that is capable of being detected or monitored by fluoroscopy, X-ray photography, CAT scan, ultrasound, or similar imaging techniques following placement into a mammalian subject.
- Preferred contrasting agents are radiopaque materials.
- the contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available. Other water insoluble contrast agents include gold, tungsten, and platinum powders. Some radiopaque contrasting agents are available in liquid form.
- the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20.degree. C.).
- the absorbable sponge material of the present invention is preferably a liquid permeable, water insoluble gelatin based sponge that has contrasting agent incorporated in the matrix of the sponge.
- incorporated is meant that the contrasting agent is substantially dispersed throughout the sponge so that the contrasting material is not simply found on the periphery of the sponge.
- the sponge is made by mixing a suitable organic solvent (e.g., formaldehyde) with an aqueous solution of gelatin.
- the organic solvent facilitates the cross linkage of gelatin polymers. It is expected that glutaraldehyde may also be suitable.
- the resulting solution is then incubated typically at slightly above room temperature (30.degree.-40.degree. C.).
- a contrasting agent is added and the resulting mixture beaten to produce a firm foam. Thereafter, the foam is dried to produce the absorbable sponge material.
- the aqueous gelatin solution containing 3-10% gelatin by weight is prepared as a warm solution (e.g., 80.degree. C.) to help dissolve the gelatin.
- the solution is then allowed to cool (e.g, 35.degree.-40.degree. C.) before the organic solvent is added.
- a preferred organic solvent is formalin (an aqueous solution of formaldehyde).
- formalin an aqueous solution of formaldehyde
- the amount of formalin used will control the hardness of the sponge and its rate of absorption into the body. The more formalin used, the harder the sponge and the lower the absorption rate. Typically, the amount used is between 0.01 to 10% based on the gelatin solution.
- the beating or whipping process takes about 5-15 or more minutes to produce a firm foam of about 4 to 8 times the volume of the original solution.
- the drying process initially begins with oven drying in the presence of circulating air at about 30.degree. to 33.degree. C. or higher and 10% humidity. After the foam is thoroughly dried, the foam can be heated to an elevated temperature of about 140.degree. C. for a sufficient length of time (e.g., 3 hrs) until the sponge is firm. Suitable absorbable sponge materials are further described in U.S. Pat. No. 2,465,357 which is incorporated herein by reference.
- the contrasting agent must be added prior to beating the gelatin/formalin solution. The reason is that once the foam material is produced, the contrasting agent cannot be incorporated into the matrix of the sponge.
- contrasting agents that are liquids it is preferred that they be added to the gelatin/formalin solution prior to being beaten to form the foam product. This will insure that the contrasting agent is dispersed throughout the sponge.
- absorbable sponge materials containing different amounts of contrasting agent were prepared and tested. Specifically, 5 grams of pork gelatin (Bloom value 275) were mixed in 100 grams of water at 80.degree. C. and the solution was allowed to cool to 35.degree. C. before 0.03 cc of 40% formalin was added. The resulting solution was incubated at 35.degree. C. for 2 hours before tantalum powder (50 to 150 grams) was added. The liquid was then vigorously mixed in a malt mixer to produce a foam. The foam was then oven dried at 35.degree. C. for 12 hours.
- the absorbable sponge material was examined with a fluoroscope and found to be extremely visible. Moreover, placement of the sponge material with contrasting agent in puncture sites of a swine model demonstrated that the absorbable sponge exhibited good hemostatic properties as well.
- the sponge material with contrasting agent of the present invention is particularly suited for biopsies and other percutaneous procedures where knowledge of the site of initial treatment, e.g., tissue removal, is important.
- the absorbable sponge material can be employed with any suitable medical instrument, a preferred device and method for facilitating hemostasis of a biopsy tract is described herein to illustrate use of the absorbable sponge material.
- the technique is further described in U.S. patent application Ser. No. 09/247,880 filed on Feb. 10, 1999 and entitled “Device and Method for Facilitating Hemostasis of a Biopsy Tract,” now U.S. Pat. No. 6,086,607, which is incorporated herein by reference.
- FIG. 1 shows the adaptor 12 in which the pledget 18 is placed for hydration and for delivery through the biopsy needle 16 .
- the adaptor 12 allows pieces of absorbable sponge material with relatively large cross sections to be easily delivered through a biopsy needle 16 with a much smaller cross section.
- the adaptor 12 also functions to remove air from the pledget 18 .
- the adaptor 12 which delivers the hydrated pledget 18 to the needle 16 includes a first end 30 having an annular lip 32 or female luer fitting for connection to the syringe 14 .
- a second end 34 of the adaptor 12 has a male luer fitting 36 for connection to a biopsy needle 16 or other cannula.
- the luer fitting 36 includes a tapered external surface 38 and a retaining ring 40 with internal threads for receiving an annular lip of the biopsy needle.
- the adaptor 12 has an internal lumen with a first diameter D.sub.1 at the first end 30 and a second diameter D.sub.2 at the second end 34 . Between the first and second ends of the adaptor 12 a tapered section 42 of the adaptor provides a funnel for compressing the hydrated pledget 18 prior to injection through the biopsy needle 16 and needle hub 28 .
- the adaptor 12 may be formed in any known manner such as by molding from a plastic material.
- the adaptor 12 is transparent so that the pledget 18 can be viewed through the adaptor and the user can visually monitor when the pledget is loaded within the adaptor and when the pledget has been delivered into the needle.
- the adaptor lumen may be provided with a friction reducing coating for improved delivery. The delivery fluid also reduces friction for improved delivery by wetting the exterior surface of the pledget 18 .
- the syringe 14 includes a male luer fitting 46 , a fluid chamber 48 , and a plunger 50 .
- the first end 30 of the adaptor 12 is connectable to the luer fitting 46 of the conventional syringe 14 .
- the syringe 14 may be provided with a spring 52 for automatic filling of the syringe 14 with a predetermined volume of fluid.
- the biopsy needle 16 used with the present invention is preferably a co-axial biopsy needle, such as a bi-axial or a tri-axial biopsy needle.
- a co-axial biopsy needle includes an outer needle or cannula through which a tissue sample is removed with a tissue scoop or other biopsy instrument. Once the tissue sample has been removed, the outer cannula remains in the patient as illustrated in FIG. 4 .
- the cannula for delivery of the sponge pledget has been described as a biopsy needle, the cannula may be a catheter, sheath, or any other type of cannula.
- FIG. 3 shows the loading and hydration of the pledget 18 within the adaptor 12 .
- a pledget 18 is cut and placed within the adaptor 12 from the first end 30 of the adaptor.
- the syringe 14 is filled with a predetermined amount of fluid, such as saline, and is connected to the first end 30 of the adaptor 12 by the luer fitting 46 .
- the plunger 50 of the syringe 14 is then depressed slowly causing fluid to pass into the adaptor 12 , hydrating the pledget 18 , and filling the adaptor with a column of fluid.
- the user waits a few seconds once the fluid is injected into the adaptor 12 until the pledget 18 is adequately hydrated creating a lubricous surface on the pledget.
- the pledget 18 may expand within the adaptor to fill or nearly fill the lumen of the adaptor.
- the adaptor 12 with the pledget 18 hydrated within the proximal end is ready to inject the pledget into a biopsy tract to facilitate hemostasis within the biopsy tract.
- the adaptor 12 may be loaded prior to beginning the biopsy procedure.
- the outer sheath of the biopsy needle 16 through which the biopsy has been taken is maintained in place within the biopsy tract, as shown in FIG. 4 .
- the biopsy needle 16 provides pre-established targeting of the delivery site for delivery of the absorbable sponge pledget 18 and eliminates the uncertainty of re-access.
- the luer fitting 36 of the adaptor 12 is connected to the biopsy needle hub 28 , as illustrated in FIG. 4 .
- the biopsy needle 16 is withdrawn a short distance, such as about 1 to 20 mm, along the biopsy tract to provide space for the pledget 18 to be received in the biopsy tract. Additional fluid is then rapidly injected by the syringe to move the pledget 18 into the biopsy needle 16 .
- the adaptor lumen When the adaptor lumen has been blocked by the hydrated pledget 18 which has swelled within the adaptor, injection of additional fluid will push the pledget through the tapered section 42 of the adaptor. If the adaptor lumen has not been entirely blocked by the pledget 18 , the venturi effect will help draw the pledget through the tapered section 42 of the adaptor.
- the pledget 18 After the pledget 18 is moved to the biopsy needle 16 , the pledget 18 is then delivered from the needle 16 to the biopsy tract by rapid injection of additional fluid by the syringe 14 .
- the hydrated pledget 18 quickly expands upon delivery to fill the available space in the biopsy tract to facilitate hemostasis and provide localized compression.
- the absorbable sponge material of the present invention can be shaped into the required size by conventional means. Pledgets may be cut with a punch or a stencil or template and knife. Once hydrated, the pledget 18 can be easily compressed to fit into a lumen having a smaller cross sectional area than the original cross sectional area of the pledget. Additionally, the kneading of the hydrated pledget 18 during delivery encourages air trapped within the absorbable sponge to be expelled and replaced with fluid, allowing rapid expansion upon delivery.
- Pledgets 118 with increased cross sectional area proximal ends may be prepared in a variety of manners.
- the increased proximal mass can be achieved by cutting the pledget with an enlarged proximal end.
- the pledget 118 may be formed by folding, rolling, compressing, or otherwise manipulating the sponge material to the desired shape.
- the proximal pledget mass may also be increased by adding separate pieces of material to the proximal end of the pledget. This additional material may be layered, wrapped, coiled or attached to the pledget in any other manner.
- the pledgets may also be formed by molding, bump extruding, dipping, or the like.
- the larger cross sectional area proximal end is generally about 1.2 to 4 times the cross sectional area of the distal end.
- the proximal end with the larger cross section area preferably extends along about 1 ⁇ 8 to 314 of the total pledget length.
- the pledget 118 illustrated in FIG. 5 has been formed by cutting a strip of material from an absorbable sponge sheet 20 with the aid of the template 122 as illustrated in FIG. 6 . After the strip is cut, the proximal end of the strip is then folded back onto itself to form a pledget 118 with an increased cross sectional area and material mass at a proximal end.
- a preferred embodiment of a pledget for delivery down a 20 gauge biopsy needle or cannula has a size of approximately 0.1.times.1.5.times.0.06 inches and is folded as illustrated in FIG. 5 to an overall length of about 0.9 inches.
- a pledget 118 in an adaptor 112 having a largest internal diameter of 0.125 inches allows the pledget to be delivered to a 20 gauge or larger biopsy needle.
- Other common biopsy procedures use an 18 gauge or larger biopsy needle through a slightly larger guide cannula and would receive a somewhat larger pledget.
- a pledget 118 maybe delivered through the cannula the biopsy site.
- the pledget 118 for use in the system employing an 18 gauge or larger biopsy needle may be formed from a strip which is approximately 0.11-0.12 inches wide by about 3.125 inches long with a thickness of about 0.06 inches and folded to an overall length of about 2.2 inches. This pledget having a 28 which is attached to the distal end of the adaptor.
- the pledget may be delivered to the biopsy tract by holding the biopsy needle or cannula 16 stationary and injecting the pledget through the biopsy needle. If additional pledgets are to be delivered, the biopsy needle 16 is withdrawn a distance sufficient to accommodate an additional pledget and the additional pledget is then injected.
- An alternative method of delivering the pledget into the biopsy tract includes withdrawing the biopsy needle or cannula 16 during delivery of the pledget 18 to deliver the pledget in an elongated trail which follows the biopsy tract. Placing the absorbable sponge material in a trail which fills the entire biopsy tract provides the added benefit of providing hemostasis along the entire biopsy tract. This is particularly helpful for stopping the bleeding of biopsy tracts in organs which tend to have excessive bleeding such as the liver, kidney, spleen, and other vascular organs.
- one method of the present invention involves the delivery of the pledget into the biopsy needle by a predetermined amount of fluid.
- the biopsy needle is then withdrawn at a velocity V while the pledget material is ejected from the biopsy needle at a velocity E with respect to the biopsy needle.
- the velocity V at which the biopsy needle is withdrawn is equal to or less than the velocity E at which the absorbable sponge material is delivered.
- the control of injection of fluid and withdrawal of the needle to achieve the desired trail of absorbable sponge material in the biopsy tract maybe controlled with an injection controlling device.
- the adaptor may be used to deliver the pledget into the biopsy needle 16 and then the adaptor is removed from the biopsy needle.
- a plunger or stylet 80 which is generally provided with the biopsy needle 16 for inserting the biopsy needle is then used to deliver the pledget from the biopsy needle.
- the biopsy needle extends through the tissue 84 and into the organ 86 for removal of a core of tissue.
- the pledget is injected into the needle 16 and the plunger 80 is placed within the biopsy needle so that a distal end of the plunger abuts the proximal end of the pledget 118 .
- the plunger 80 is then held stationary while the biopsy needle 16 is withdrawn from the biopsy site.
- the plunger 80 causes the pledget 118 to be delivered in a trail 88 which fills the biopsy tract.
- the trail 88 preferably extends along the entire biopsy tract to or past a surface of the organ 86 .
- the delivery of the trail 88 of absorbable sponge material provides an advantage over the delivery of discrete blobs of material because the trail is able to provide hemostasis along the entire tract.
- a blob of absorbable sponge material is delivered within the tract at a depth of 1-2 cm from the surface of the organs, this 1-2 cm of biopsy tract may continue to bleed significantly.
- the pledget may be delivered as a plug.
- the plunger 80 is advanced into the needle 16 pushing the pledget out of the distal end of the needle while the needle is held stationary.
- a combination of delivery of plugs and trails may also be used.
- the pledget material may be delivered entirely within a single anatomical structure or may cross two or more anatomical structures such as an organ, surrounding tissue and facial layer.
- the biopsy needle 16 is retracted a distance sufficient to provide a space to accommodate an additional pledget 18 and the injection procedure described above is repeated for the additional pledget(s).
- additional pledgets 18 may be injected beside an initially injected pledget until the cavity is filled.
- biopsy is most commonly performed by biopsy needle, biopsy may also be performed through other cannulas, such as catheters, long needles, endoscopes, or the like.
- the treatment procedure according to the present invention can be used for facilitating hemostasis of puncture wounds through different types of cannulas including needles, catheters, endoscopes, and the like.
- the treatment procedure and systems according to the present invention may be used to deliver absorbable or non-absorbable sponge for other therapys.
- sponge may be delivered for cosmetic or reconstructive bulking or for temporary or permanent intravascular embolization.
- the absorbable sponge pledget 18 may be used to deliver a beneficial agent, such as, thrombin, radiation treatment, or the like.
- the pledget can also be used to deliver therapeutic agents, such as radioactive isotopes for localized treatment of tumors, anti-cancer agents, anti-metastatic agents, and the like.
- therapeutic agents such as radioactive isotopes for localized treatment of tumors, anti-cancer agents, anti-metastatic agents, and the like.
- anti-cancer agents include 5-fluorouracil, cisplatin, prednisone, and others described in U.S. Pat. No. 4,619,913 which is incorporated herein by reference.
- the absorbable sponge pledget 18 may be presoaked with the beneficial agent for delivery to the biopsy tract.
- the pledget 18 may be hydrated with the beneficial liquid agent or the agent may be delivered to the pledget after the pledget is placed within the biopsy tract.
- a pledget formed of inventive absorbable sponge material preferably will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be designed to provide different rates of absorption. If the contrasting agent employed is also absorbable, the contrasting agent should be absorbed at approximately the same rate as the sponge material. Where the contrasting agent is non-absorbable, it will remain at the site.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- Optics & Photonics (AREA)
- Hematology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Surgical Instruments (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Abstract
An absorbable sponge containing a contrasting agent (e.g, radiopaque agent) that can be introduced to a biopsy tract or other puncture wound site is provided. The contrasting agent permits identification of the site by fluoroscopy or other imaging techniques.
Description
- This application is a continuation of U.S. application Ser. No. 12/578,088 filed Oct. 13, 2009, which is a continuation of U.S. application Ser. No. 10/978,321, filed Oct. 29, 2004, now U.S. Pat. No. 7,618,567, which is a divisional of U.S. application Ser. No. 09/966,611, filed Sep. 27, 2001, now abandoned, which is a continuation of U.S. application Ser. No. 09/630,814, filed Aug. 2, 2000, now abandoned, which is a divisional of U.S. application Ser. No. 09/335,452, filed Jun. 17, 1999, now U.S. Pat. No. 6,183,497, which is a continuation in part of U.S. application Ser. No. 09/071,670, filed May 1, 1998, now U.S. Pat. No. 6,071,301 and U.S. application Ser. No. 09/071,284, filed May 1, 1998, now U.S. Pat. No. 6,162,192.
- 1. Field of the Invention
- The invention relates to an absorbable sponge, and more particularly, the invention relates to the delivery of a contrasting agent to a specific area or site in a mammal after a surgical or interventional procedure. The contrasting agent facilitates the location of the area or site even weeks or months after the initial procedure.
- 2. Brief Description of the Related Art
- Percutaneous needle biopsy of solid organs is one of the most common interventional medical procedures. Millions of percutaneous needle biopsies are performed annually in the United States and throughout the world. Percutaneous biopsy is a safe procedure which has supplanted surgical biopsy for many indications, such as biopsy and liver biopsy.
- Possible complications of needle biopsy include bleeding at the biopsy site. The amount of bleeding is related to a number of factors including needle size, tissue sample size, patient's coagulation status, and the location of the biopsy site. Vascular organs such as the liver, a common biopsy target, may bleed significantly after needle biopsy.
- Sterile sponges, such as GELFOAM, are prepared in dry sterile sheets which are used as packing material during surgery for control of bleeding. The sponge sheets are left in the surgical site after surgery to stop bleeding and are absorbed by the body. A number of techniques have used these absorbable sterile sponge materials to plug a biopsy tract to minimize or prevent bleeding. The absorbable sponge provides a mechanical blockage of the tract, encourages clotting, and minimizes bleeding though the biopsy tract.
- During the biopsy, a mechanic clip device is often attached to the site where tissue is removed, so that if further treatment is later required the location of the site can be identified. Unfortunately, the time period between the biopsy and treatment may be weeks during which time the clip may become dislodged thereby making it difficult to relocate the site.
- Accordingly, it would be desirable to provide a reliable technique for identifying biopsy sites or puncture wound sites.
- The present invention is based in part on the discovery that adding a contrasting agent (e.g, radiopaque agent) to an absorbable sponge provides for a material that not only facilitates hemostasis of a biopsy tract or other puncture wound but also permits precise identification of the site's location.
- Accordingly, in one aspect, the invention is directed to a method for marking a bodily site in a patient that includes the steps of:
- identifying the bodily site; and
- positioning a pledget of absorbable sponge material adjacent the bodily site wherein the absorbable sponge material includes a contrasting agent.
- With the present invention, the exact location of the bodily site can be located many weeks or longer following positioning of the absorbable sponge material.
- In another aspect, the invention is directed to a method for performing a biopsy that included the steps of:
- removing tissue from a vascular tissue site; and
- positioning a pledget of absorbable sponge material adjacent the vascular tissue site wherein the absorbable sponge material includes a contrasting agent.
- In another aspect, the invention is directed to a liquid permeable, absorbable, gelatin sponge that is prepared by a process that includes the steps of:
- (a) preparing an aqueous gelatin solution;
- (b) adding an organic solvent in the aqueous gelatin solution to form a second solution;
- (c) incubating the second solution;
- (d) forming a foam from the second solution wherein a contrasting agent is added to the second solution at any step prior to forming the foam; and
- (e) drying the foam.
- The invention will now be described in greater detail with referee to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
-
FIG. 1 is a side cross sectional view of an adaptor for delivery of a pledget to a needle; -
FIG. 2 is a side cross sectional view of a syringe for connection to the adaptor; -
FIG. 3 is a side cross sectional view of an adaptor and syringe combination with a pledget positioned within the adaptor; -
FIG. 4 is a side cross sectional view of the loaded adaptor and syringe combination in preparation for connection to a biopsy needle; -
FIG. 5 is a side cross sectional view of an alternative embodiment of an adaptor for delivery of a pledget including a template attached to the adaptor; -
FIG. 6 is a top view of the template as it is used for cutting a pledget from an absorbable sponge sheet; and -
FIG. 7 is a side cross sectional view of a portion of an organ and a system for delivering a pledget into a biopsy tract in the organ. - The present invention is directed to an absorbable sponge material containing a contrasting agent. The absorbable sponge material is delivered to a specific area or site in a patient (i.e., mammal) after a surgical or interventional procedure. For example, the sponge material can be placed in the biopsy tract or other puncture wound and the contrasting agent enables marking or identification of the area or site. The absorbable sponge will be described in connection with treatment of a biopsy tract after a percutaneous needle biopsy. The absorbable sponge material can also exhibit secondary benefits of, for example, facilitating hemostasis and delivering therapeutic agents.
- Prior to discussing the present invention in further detail, the following terms are defined:
- “Pledget” means a piece of absorbable sponge containing a contrasting agent preferably of a generally elongated shape having a size which allows injection in a hydrated state through a biopsy needle or other cannula.
- “Sponge” means a biocompatible material which is capable of being hydrated and is resiliently compressible in a hydrated state. Preferably, the sponge is non-immunogenic and is absorbable.
- “Absorbable sponge” means a sponge which when implanted within a patient (i.e., human or other mammalian body) is absorbed by the body. The absorbable sponge contains a contrasting agent which may or may not be absorbable. Besides the contrasting agent, the sponge can also be used to deliver a beneficial agent such as thrombin, radiation treatment or the like.
- “Bodily site” means any tissue in a mammal where the absorbable sponge containing the contrasting agent can be introduced. The invention is particularly suited for introducing the absorbable sponge into tissue sites where further treatment may be required, for example, as in the case following biopsy.
- “Hydrate” means to partially or fully saturate with a fluid, such as, saline, water, or the like.
- “Kneading” of the absorbable sponge material means both dry and wet manipulation of the sponge material which compresses, enlarges, or changes the shape of the sponge material causing the sponge material to have improved expansion response.
- “Contrasting agent” means a biocompatible material that is capable of being detected or monitored by fluoroscopy, X-ray photography, CAT scan, ultrasound, or similar imaging techniques following placement into a mammalian subject. Preferred contrasting agents are radiopaque materials. The contrast agent can be either water soluble or water insoluble. Examples of water soluble contrast agents include metrizamide, iopamidol, iothalamate sodium, iodomide sodium, and meglumine. Examples of water insoluble contrast agents include tantalum, tantalum oxide, and barium sulfate, each of which is commercially available. Other water insoluble contrast agents include gold, tungsten, and platinum powders. Some radiopaque contrasting agents are available in liquid form. These include, for example, OMNIPAQUE from Nycomed, Inc., Princeton, N.J. Preferably, the contrast agent is water insoluble (i.e., has a water solubility of less than 0.01 mg/ml at 20.degree. C.).
- The absorbable sponge material of the present invention is preferably a liquid permeable, water insoluble gelatin based sponge that has contrasting agent incorporated in the matrix of the sponge. By “incorporated” is meant that the contrasting agent is substantially dispersed throughout the sponge so that the contrasting material is not simply found on the periphery of the sponge. The sponge is made by mixing a suitable organic solvent (e.g., formaldehyde) with an aqueous solution of gelatin. The organic solvent facilitates the cross linkage of gelatin polymers. It is expected that glutaraldehyde may also be suitable. The resulting solution is then incubated typically at slightly above room temperature (30.degree.-40.degree. C.). Subsequently, a contrasting agent is added and the resulting mixture beaten to produce a firm foam. Thereafter, the foam is dried to produce the absorbable sponge material.
- Typically, the aqueous gelatin solution containing 3-10% gelatin by weight is prepared as a warm solution (e.g., 80.degree. C.) to help dissolve the gelatin. The solution is then allowed to cool (e.g, 35.degree.-40.degree. C.) before the organic solvent is added. A preferred organic solvent is formalin (an aqueous solution of formaldehyde). The amount of formalin used will control the hardness of the sponge and its rate of absorption into the body. The more formalin used, the harder the sponge and the lower the absorption rate. Typically, the amount used is between 0.01 to 10% based on the gelatin solution. The beating or whipping process takes about 5-15 or more minutes to produce a firm foam of about 4 to 8 times the volume of the original solution. The drying process initially begins with oven drying in the presence of circulating air at about 30.degree. to 33.degree. C. or higher and 10% humidity. After the foam is thoroughly dried, the foam can be heated to an elevated temperature of about 140.degree. C. for a sufficient length of time (e.g., 3 hrs) until the sponge is firm. Suitable absorbable sponge materials are further described in U.S. Pat. No. 2,465,357 which is incorporated herein by reference.
- It has been found that at least for contrasting agents that are not soluble in water, the contrasting agent must be added prior to beating the gelatin/formalin solution. The reason is that once the foam material is produced, the contrasting agent cannot be incorporated into the matrix of the sponge.
- When employing contrasting agents that are liquids it is preferred that they be added to the gelatin/formalin solution prior to being beaten to form the foam product. This will insure that the contrasting agent is dispersed throughout the sponge.
- Care should be taken when using insoluble contrasting agents not to overload the absorbable sponge material by using excessive amounts of contrasting agents. This will possibly result in sponges that have reduced cell structures, that is, the final volume will be significantly less than if no contrasting agent was used.
- Following the above formulation, absorbable sponge materials containing different amounts of contrasting agent were prepared and tested. Specifically, 5 grams of pork gelatin (Bloom value 275) were mixed in 100 grams of water at 80.degree. C. and the solution was allowed to cool to 35.degree. C. before 0.03 cc of 40% formalin was added. The resulting solution was incubated at 35.degree. C. for 2 hours before tantalum powder (50 to 150 grams) was added. The liquid was then vigorously mixed in a malt mixer to produce a foam. The foam was then oven dried at 35.degree. C. for 12 hours.
- The absorbable sponge material was examined with a fluoroscope and found to be extremely visible. Moreover, placement of the sponge material with contrasting agent in puncture sites of a swine model demonstrated that the absorbable sponge exhibited good hemostatic properties as well.
- The sponge material with contrasting agent of the present invention is particularly suited for biopsies and other percutaneous procedures where knowledge of the site of initial treatment, e.g., tissue removal, is important.
- While the absorbable sponge material can be employed with any suitable medical instrument, a preferred device and method for facilitating hemostasis of a biopsy tract is described herein to illustrate use of the absorbable sponge material. The technique is further described in U.S. patent application Ser. No. 09/247,880 filed on Feb. 10, 1999 and entitled “Device and Method for Facilitating Hemostasis of a Biopsy Tract,” now U.S. Pat. No. 6,086,607, which is incorporated herein by reference.
-
FIG. 1 shows theadaptor 12 in which thepledget 18 is placed for hydration and for delivery through thebiopsy needle 16. Theadaptor 12 allows pieces of absorbable sponge material with relatively large cross sections to be easily delivered through abiopsy needle 16 with a much smaller cross section. Theadaptor 12 also functions to remove air from thepledget 18. - The
adaptor 12 which delivers thehydrated pledget 18 to theneedle 16 includes afirst end 30 having anannular lip 32 or female luer fitting for connection to thesyringe 14. Asecond end 34 of theadaptor 12 has a male luer fitting 36 for connection to abiopsy needle 16 or other cannula. The luer fitting 36 includes a taperedexternal surface 38 and a retainingring 40 with internal threads for receiving an annular lip of the biopsy needle. Theadaptor 12 has an internal lumen with a first diameter D.sub.1 at thefirst end 30 and a second diameter D.sub.2 at thesecond end 34. Between the first and second ends of the adaptor 12 a taperedsection 42 of the adaptor provides a funnel for compressing thehydrated pledget 18 prior to injection through thebiopsy needle 16 andneedle hub 28. - The
adaptor 12 may be formed in any known manner such as by molding from a plastic material. Preferably, theadaptor 12 is transparent so that thepledget 18 can be viewed through the adaptor and the user can visually monitor when the pledget is loaded within the adaptor and when the pledget has been delivered into the needle. The adaptor lumen may be provided with a friction reducing coating for improved delivery. The delivery fluid also reduces friction for improved delivery by wetting the exterior surface of thepledget 18. - As shown in
FIG. 2 , thesyringe 14 includes a male luer fitting 46, afluid chamber 48, and aplunger 50. Thefirst end 30 of theadaptor 12 is connectable to the luer fitting 46 of theconventional syringe 14. Thesyringe 14 may be provided with a spring 52 for automatic filling of thesyringe 14 with a predetermined volume of fluid. - The
biopsy needle 16 used with the present invention is preferably a co-axial biopsy needle, such as a bi-axial or a tri-axial biopsy needle. A co-axial biopsy needle includes an outer needle or cannula through which a tissue sample is removed with a tissue scoop or other biopsy instrument. Once the tissue sample has been removed, the outer cannula remains in the patient as illustrated inFIG. 4 . Although the cannula for delivery of the sponge pledget has been described as a biopsy needle, the cannula may be a catheter, sheath, or any other type of cannula. - A preferred method of facilitating hemostasis of a biopsy tract will be described with reference to
FIG. 3 which shows the loading and hydration of thepledget 18 within theadaptor 12. Apledget 18 is cut and placed within theadaptor 12 from thefirst end 30 of the adaptor. Thesyringe 14 is filled with a predetermined amount of fluid, such as saline, and is connected to thefirst end 30 of theadaptor 12 by theluer fitting 46. Theplunger 50 of thesyringe 14 is then depressed slowly causing fluid to pass into theadaptor 12, hydrating thepledget 18, and filling the adaptor with a column of fluid. Care should be taken to inject the fluid slowly to prevent the pledget from being ejected out of thesecond end 34 of the adaptor. Preferably, the user waits a few seconds once the fluid is injected into theadaptor 12 until thepledget 18 is adequately hydrated creating a lubricous surface on the pledget. Thepledget 18 may expand within the adaptor to fill or nearly fill the lumen of the adaptor. Theadaptor 12 with thepledget 18 hydrated within the proximal end is ready to inject the pledget into a biopsy tract to facilitate hemostasis within the biopsy tract. Theadaptor 12 may be loaded prior to beginning the biopsy procedure. - After the biopsy procedure has been completed, the outer sheath of the
biopsy needle 16 through which the biopsy has been taken is maintained in place within the biopsy tract, as shown inFIG. 4 . Thebiopsy needle 16 provides pre-established targeting of the delivery site for delivery of theabsorbable sponge pledget 18 and eliminates the uncertainty of re-access. The luer fitting 36 of theadaptor 12 is connected to thebiopsy needle hub 28, as illustrated inFIG. 4 . Thebiopsy needle 16 is withdrawn a short distance, such as about 1 to 20 mm, along the biopsy tract to provide space for thepledget 18 to be received in the biopsy tract. Additional fluid is then rapidly injected by the syringe to move thepledget 18 into thebiopsy needle 16. When the adaptor lumen has been blocked by thehydrated pledget 18 which has swelled within the adaptor, injection of additional fluid will push the pledget through the taperedsection 42 of the adaptor. If the adaptor lumen has not been entirely blocked by thepledget 18, the venturi effect will help draw the pledget through the taperedsection 42 of the adaptor. After thepledget 18 is moved to thebiopsy needle 16, thepledget 18 is then delivered from theneedle 16 to the biopsy tract by rapid injection of additional fluid by thesyringe 14. Thehydrated pledget 18 quickly expands upon delivery to fill the available space in the biopsy tract to facilitate hemostasis and provide localized compression. - The absorbable sponge material of the present invention can be shaped into the required size by conventional means. Pledgets may be cut with a punch or a stencil or template and knife. Once hydrated, the
pledget 18 can be easily compressed to fit into a lumen having a smaller cross sectional area than the original cross sectional area of the pledget. Additionally, the kneading of thehydrated pledget 18 during delivery encourages air trapped within the absorbable sponge to be expelled and replaced with fluid, allowing rapid expansion upon delivery. - When delivering a
pledget 118 of absorbable sponge material, it is important to deliver a desired amount of the sponge material using a minimum amount of fluid. -
Pledgets 118 with increased cross sectional area proximal ends may be prepared in a variety of manners. For example, if apledget 118 is prepared from a sheet of sponge material, the increased proximal mass can be achieved by cutting the pledget with an enlarged proximal end. Alternatively, thepledget 118 may be formed by folding, rolling, compressing, or otherwise manipulating the sponge material to the desired shape. The proximal pledget mass may also be increased by adding separate pieces of material to the proximal end of the pledget. This additional material may be layered, wrapped, coiled or attached to the pledget in any other manner. The pledgets may also be formed by molding, bump extruding, dipping, or the like. The larger cross sectional area proximal end is generally about 1.2 to 4 times the cross sectional area of the distal end. In addition, the proximal end with the larger cross section area preferably extends along about ⅛ to 314 of the total pledget length. - The
pledget 118 illustrated inFIG. 5 has been formed by cutting a strip of material from anabsorbable sponge sheet 20 with the aid of thetemplate 122 as illustrated inFIG. 6 . After the strip is cut, the proximal end of the strip is then folded back onto itself to form apledget 118 with an increased cross sectional area and material mass at a proximal end. One example of a preferred embodiment of a pledget for delivery down a 20 gauge biopsy needle or cannula has a size of approximately 0.1.times.1.5.times.0.06 inches and is folded as illustrated inFIG. 5 to an overall length of about 0.9 inches. Placing thispledget 118 in anadaptor 112 having a largest internal diameter of 0.125 inches allows the pledget to be delivered to a 20 gauge or larger biopsy needle. Other common biopsy procedures use an 18 gauge or larger biopsy needle through a slightly larger guide cannula and would receive a somewhat larger pledget. After taking a core sample and removing the biopsy needle from the cannula guide, apledget 118 maybe delivered through the cannula the biopsy site. Thepledget 118 for use in the system employing an 18 gauge or larger biopsy needle may be formed from a strip which is approximately 0.11-0.12 inches wide by about 3.125 inches long with a thickness of about 0.06 inches and folded to an overall length of about 2.2 inches. This pledget having a 28 which is attached to the distal end of the adaptor. - As described above, the pledget may be delivered to the biopsy tract by holding the biopsy needle or
cannula 16 stationary and injecting the pledget through the biopsy needle. If additional pledgets are to be delivered, thebiopsy needle 16 is withdrawn a distance sufficient to accommodate an additional pledget and the additional pledget is then injected. - An alternative method of delivering the pledget into the biopsy tract includes withdrawing the biopsy needle or
cannula 16 during delivery of thepledget 18 to deliver the pledget in an elongated trail which follows the biopsy tract. Placing the absorbable sponge material in a trail which fills the entire biopsy tract provides the added benefit of providing hemostasis along the entire biopsy tract. This is particularly helpful for stopping the bleeding of biopsy tracts in organs which tend to have excessive bleeding such as the liver, kidney, spleen, and other vascular organs. - In order to achieve a trail of absorbable sponge material in the biopsy tract, one method of the present invention involves the delivery of the pledget into the biopsy needle by a predetermined amount of fluid. The biopsy needle is then withdrawn at a velocity V while the pledget material is ejected from the biopsy needle at a velocity E with respect to the biopsy needle. The velocity V at which the biopsy needle is withdrawn is equal to or less than the velocity E at which the absorbable sponge material is delivered. The control of injection of fluid and withdrawal of the needle to achieve the desired trail of absorbable sponge material in the biopsy tract maybe controlled with an injection controlling device.
- According to an alternative embodiment as illustrated in
FIG. 7 , the adaptor may be used to deliver the pledget into thebiopsy needle 16 and then the adaptor is removed from the biopsy needle. A plunger orstylet 80 which is generally provided with thebiopsy needle 16 for inserting the biopsy needle is then used to deliver the pledget from the biopsy needle. As shown inFIG. 7 , the biopsy needle extends through thetissue 84 and into theorgan 86 for removal of a core of tissue. After biopsy, the pledget is injected into theneedle 16 and theplunger 80 is placed within the biopsy needle so that a distal end of the plunger abuts the proximal end of thepledget 118. Theplunger 80 is then held stationary while thebiopsy needle 16 is withdrawn from the biopsy site. Theplunger 80 causes thepledget 118 to be delivered in atrail 88 which fills the biopsy tract. Thetrail 88 preferably extends along the entire biopsy tract to or past a surface of theorgan 86. The delivery of thetrail 88 of absorbable sponge material provides an advantage over the delivery of discrete blobs of material because the trail is able to provide hemostasis along the entire tract. In contrast, if a blob of absorbable sponge material is delivered within the tract at a depth of 1-2 cm from the surface of the organs, this 1-2 cm of biopsy tract may continue to bleed significantly. - As an alternative to delivery of the pledget as a trail, the pledget may be delivered as a plug. To deliver a plug the
plunger 80 is advanced into theneedle 16 pushing the pledget out of the distal end of the needle while the needle is held stationary. A combination of delivery of plugs and trails may also be used. The pledget material may be delivered entirely within a single anatomical structure or may cross two or more anatomical structures such as an organ, surrounding tissue and facial layer. - In some instances it may be desirable to deliver multiple pledgets in spaced apart positions along the biopsy tract, particularly for a long biopsy tract. For delivery of additional pledgets, the
biopsy needle 16 is retracted a distance sufficient to provide a space to accommodate anadditional pledget 18 and the injection procedure described above is repeated for the additional pledget(s). For a particularly large biopsy site or cavity,additional pledgets 18 may be injected beside an initially injected pledget until the cavity is filled. - Although biopsy is most commonly performed by biopsy needle, biopsy may also be performed through other cannulas, such as catheters, long needles, endoscopes, or the like. The treatment procedure according to the present invention can be used for facilitating hemostasis of puncture wounds through different types of cannulas including needles, catheters, endoscopes, and the like. In addition, the treatment procedure and systems according to the present invention may be used to deliver absorbable or non-absorbable sponge for other therapys. For example, sponge may be delivered for cosmetic or reconstructive bulking or for temporary or permanent intravascular embolization.
- In addition to the contrasting agent, the
absorbable sponge pledget 18 may be used to deliver a beneficial agent, such as, thrombin, radiation treatment, or the like. The pledget can also be used to deliver therapeutic agents, such as radioactive isotopes for localized treatment of tumors, anti-cancer agents, anti-metastatic agents, and the like. Examples of anti-cancer agents include 5-fluorouracil, cisplatin, prednisone, and others described in U.S. Pat. No. 4,619,913 which is incorporated herein by reference. Theabsorbable sponge pledget 18 may be presoaked with the beneficial agent for delivery to the biopsy tract. Alternatively, thepledget 18 may be hydrated with the beneficial liquid agent or the agent may be delivered to the pledget after the pledget is placed within the biopsy tract. - A pledget formed of inventive absorbable sponge material preferably will be absorbed by the body within 1 to 6 weeks. However, the pledget material may be designed to provide different rates of absorption. If the contrasting agent employed is also absorbable, the contrasting agent should be absorbed at approximately the same rate as the sponge material. Where the contrasting agent is non-absorbable, it will remain at the site.
- While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
Claims (1)
1. A liquid permeable, absorbable gelatin sponge that is prepared by a process that comprises: (a) preparing an aqueous gelatin solution; (b) adding an organic solvent in the aqueous gelatin solution to form a second solution; (c) incubating the second solution; (d) forming a foam from the second solution wherein a contrasting agent is added to the second solution at any step prior to forming the foam; and (e) drying the foam.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/776,952 US20130172737A1 (en) | 1998-05-01 | 2013-02-26 | Absorbable sponge with contrasting agent |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/071,284 US6162192A (en) | 1998-05-01 | 1998-05-01 | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
US09/071,670 US6071301A (en) | 1998-05-01 | 1998-05-01 | Device and method for facilitating hemostasis of a biopsy tract |
US09/335,452 US6183497B1 (en) | 1998-05-01 | 1999-06-17 | Absorbable sponge with contrasting agent |
US63081400A | 2000-08-02 | 2000-08-02 | |
US09/966,611 US20020038133A1 (en) | 1998-05-01 | 2001-09-27 | Absorbable sponge with contrasting agent |
US10/978,321 US7618567B2 (en) | 1998-05-01 | 2004-10-29 | Absorbable sponge with contrasting agent |
US12/578,088 US20100029908A1 (en) | 1998-05-01 | 2009-10-13 | Absorbable sponge with contrasting agent |
US13/776,952 US20130172737A1 (en) | 1998-05-01 | 2013-02-26 | Absorbable sponge with contrasting agent |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/578,088 Continuation US20100029908A1 (en) | 1995-09-15 | 2009-10-13 | Absorbable sponge with contrasting agent |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130172737A1 true US20130172737A1 (en) | 2013-07-04 |
Family
ID=23311845
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/335,452 Expired - Lifetime US6183497B1 (en) | 1995-09-15 | 1999-06-17 | Absorbable sponge with contrasting agent |
US09/966,611 Abandoned US20020038133A1 (en) | 1995-09-15 | 2001-09-27 | Absorbable sponge with contrasting agent |
US10/978,321 Expired - Fee Related US7618567B2 (en) | 1995-09-15 | 2004-10-29 | Absorbable sponge with contrasting agent |
US12/578,088 Abandoned US20100029908A1 (en) | 1995-09-15 | 2009-10-13 | Absorbable sponge with contrasting agent |
US13/776,952 Abandoned US20130172737A1 (en) | 1998-05-01 | 2013-02-26 | Absorbable sponge with contrasting agent |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/335,452 Expired - Lifetime US6183497B1 (en) | 1995-09-15 | 1999-06-17 | Absorbable sponge with contrasting agent |
US09/966,611 Abandoned US20020038133A1 (en) | 1995-09-15 | 2001-09-27 | Absorbable sponge with contrasting agent |
US10/978,321 Expired - Fee Related US7618567B2 (en) | 1995-09-15 | 2004-10-29 | Absorbable sponge with contrasting agent |
US12/578,088 Abandoned US20100029908A1 (en) | 1995-09-15 | 2009-10-13 | Absorbable sponge with contrasting agent |
Country Status (6)
Country | Link |
---|---|
US (5) | US6183497B1 (en) |
EP (1) | EP1191884A1 (en) |
JP (1) | JP4460203B2 (en) |
AU (1) | AU5877200A (en) |
CA (1) | CA2371841A1 (en) |
WO (1) | WO2000078228A1 (en) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996008208A1 (en) * | 1994-09-16 | 1996-03-21 | Biopsys Medical, Inc. | Methods and devices for defining and marking tissue |
US6071301A (en) | 1998-05-01 | 2000-06-06 | Sub Q., Inc. | Device and method for facilitating hemostasis of a biopsy tract |
US6183497B1 (en) * | 1998-05-01 | 2001-02-06 | Sub-Q, Inc. | Absorbable sponge with contrasting agent |
US6071300A (en) * | 1995-09-15 | 2000-06-06 | Sub-Q Inc. | Apparatus and method for percutaneous sealing of blood vessel punctures |
US7637948B2 (en) | 1997-10-10 | 2009-12-29 | Senorx, Inc. | Tissue marking implant |
US8668737B2 (en) | 1997-10-10 | 2014-03-11 | Senorx, Inc. | Tissue marking implant |
US6270464B1 (en) * | 1998-06-22 | 2001-08-07 | Artemis Medical, Inc. | Biopsy localization method and device |
US6161034A (en) * | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US6347241B2 (en) * | 1999-02-02 | 2002-02-12 | Senorx, Inc. | Ultrasonic and x-ray detectable biopsy site marker and apparatus for applying it |
US6610026B2 (en) | 1998-05-01 | 2003-08-26 | Sub-Q, Inc. | Method of hydrating a sponge material for delivery to a body |
US6315753B1 (en) * | 1998-05-01 | 2001-11-13 | Sub-Q, Inc. | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
US20010045575A1 (en) * | 1998-05-01 | 2001-11-29 | Mark Ashby | Device and method for facilitating hemostasis of a biopsy tract |
US6200328B1 (en) | 1998-05-01 | 2001-03-13 | Sub Q, Incorporated | Device and method for facilitating hemostasis of a biopsy tract |
US20020058882A1 (en) * | 1998-06-22 | 2002-05-16 | Artemis Medical, Incorporated | Biopsy localization method and device |
US6356782B1 (en) | 1998-12-24 | 2002-03-12 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US6371904B1 (en) * | 1998-12-24 | 2002-04-16 | Vivant Medical, Inc. | Subcutaneous cavity marking device and method |
US9669113B1 (en) | 1998-12-24 | 2017-06-06 | Devicor Medical Products, Inc. | Device and method for safe location and marking of a biopsy cavity |
US6862470B2 (en) | 1999-02-02 | 2005-03-01 | Senorx, Inc. | Cavity-filling biopsy site markers |
US8498693B2 (en) | 1999-02-02 | 2013-07-30 | Senorx, Inc. | Intracorporeal marker and marker delivery device |
US7983734B2 (en) | 2003-05-23 | 2011-07-19 | Senorx, Inc. | Fibrous marker and intracorporeal delivery thereof |
US20090030309A1 (en) | 2007-07-26 | 2009-01-29 | Senorx, Inc. | Deployment of polysaccharide markers |
US7651505B2 (en) | 2002-06-17 | 2010-01-26 | Senorx, Inc. | Plugged tip delivery for marker placement |
US8361082B2 (en) | 1999-02-02 | 2013-01-29 | Senorx, Inc. | Marker delivery device with releasable plug |
US20080039819A1 (en) * | 2006-08-04 | 2008-02-14 | Senorx, Inc. | Marker formed of starch or other suitable polysaccharide |
US9820824B2 (en) | 1999-02-02 | 2017-11-21 | Senorx, Inc. | Deployment of polysaccharide markers for treating a site within a patent |
US6725083B1 (en) * | 1999-02-02 | 2004-04-20 | Senorx, Inc. | Tissue site markers for in VIVO imaging |
EP1156741B1 (en) * | 1999-02-10 | 2010-12-22 | Sub-Q, Inc. | Device for facilitating hemostasis of a biopsy tract |
US6575991B1 (en) | 1999-06-17 | 2003-06-10 | Inrad, Inc. | Apparatus for the percutaneous marking of a lesion |
US7695492B1 (en) | 1999-09-23 | 2010-04-13 | Boston Scientific Scimed, Inc. | Enhanced bleed back system |
WO2002041786A2 (en) | 2000-11-20 | 2002-05-30 | Senorx, Inc. | Tissue site markers for in vivo imaging |
EP1406671A1 (en) * | 2001-03-12 | 2004-04-14 | Sub Q, Inc. | Methods for sterilizing cross-linked gelatin compositions |
US8187625B2 (en) * | 2001-03-12 | 2012-05-29 | Boston Scientific Scimed, Inc. | Cross-linked gelatin composition comprising a wetting agent |
US6511457B2 (en) * | 2001-05-04 | 2003-01-28 | Garey Thompson | Airless syringe |
US7008440B2 (en) * | 2001-11-08 | 2006-03-07 | Sub-Q, Inc. | System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
US6863680B2 (en) * | 2001-11-08 | 2005-03-08 | Sub-Q, Inc. | System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
US8877233B2 (en) * | 2001-06-29 | 2014-11-04 | Cook Biotech Incorporated | Porous sponge matrix medical devices and methods |
US7025748B2 (en) * | 2001-11-08 | 2006-04-11 | Boston Scientific Scimed, Inc. | Sheath based blood vessel puncture locator and depth indicator |
US7037323B2 (en) * | 2001-11-08 | 2006-05-02 | Sub-Q, Inc. | Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
US7192436B2 (en) * | 2001-11-08 | 2007-03-20 | Sub-Q, Inc. | Pledget-handling system and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
AU2003231312B2 (en) * | 2002-05-06 | 2008-10-23 | Drexel University | Tissue joining devices capable of delivery of bioactive agents and methods for use thereof |
US20040102730A1 (en) * | 2002-10-22 | 2004-05-27 | Davis Thomas P. | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
AU2003275607A1 (en) * | 2002-10-24 | 2004-05-13 | Terumo Kabushiki Kaisha | Method of producing syringe, cap, and prefilled syringe |
US7955353B1 (en) | 2002-11-04 | 2011-06-07 | Sub-Q, Inc. | Dissolvable closure device |
US7455680B1 (en) | 2002-11-04 | 2008-11-25 | Boston Scientific Scimed, Inc. | Apparatus and method for inhibiting blood loss |
US8317821B1 (en) | 2002-11-04 | 2012-11-27 | Boston Scientific Scimed, Inc. | Release mechanism |
US20060036158A1 (en) | 2003-11-17 | 2006-02-16 | Inrad, Inc. | Self-contained, self-piercing, side-expelling marking apparatus |
US20040122349A1 (en) * | 2002-12-20 | 2004-06-24 | Lafontaine Daniel M. | Closure device with textured surface |
US8709038B2 (en) * | 2002-12-20 | 2014-04-29 | Boston Scientific Scimed, Inc. | Puncture hole sealing device |
US20050119562A1 (en) * | 2003-05-23 | 2005-06-02 | Senorx, Inc. | Fibrous marker formed of synthetic polymer strands |
US7877133B2 (en) | 2003-05-23 | 2011-01-25 | Senorx, Inc. | Marker or filler forming fluid |
US7942897B2 (en) * | 2003-07-10 | 2011-05-17 | Boston Scientific Scimed, Inc. | System for closing an opening in a body cavity |
US7744852B2 (en) | 2003-07-25 | 2010-06-29 | Rubicor Medical, Llc | Methods and systems for marking post biopsy cavity sites |
US7537788B2 (en) | 2003-07-25 | 2009-05-26 | Rubicor Medical, Inc. | Post-biopsy cavity treatment implants and methods |
US20050020899A1 (en) * | 2003-07-25 | 2005-01-27 | Rubicor Medical, Inc. | Post-biopsy cavity treatmetn implants and methods |
US20050273002A1 (en) | 2004-06-04 | 2005-12-08 | Goosen Ryan L | Multi-mode imaging marker |
US7875043B1 (en) | 2003-12-09 | 2011-01-25 | Sub-Q, Inc. | Cinching loop |
US20050234336A1 (en) * | 2004-03-26 | 2005-10-20 | Beckman Andrew T | Apparatus and method for marking tissue |
US10357328B2 (en) | 2005-04-20 | 2019-07-23 | Bard Peripheral Vascular, Inc. and Bard Shannon Limited | Marking device with retractable cannula |
CA2562580C (en) | 2005-10-07 | 2014-04-29 | Inrad, Inc. | Drug-eluting tissue marker |
GB0521536D0 (en) * | 2005-10-22 | 2005-11-30 | Invibio Ltd | Fiducial marker |
US20080234532A1 (en) * | 2005-10-22 | 2008-09-25 | Invibio Limited | Fiducial marker |
US20070129630A1 (en) * | 2005-12-07 | 2007-06-07 | Shimko Daniel A | Imaging method, device and system |
US20070135706A1 (en) * | 2005-12-13 | 2007-06-14 | Shimko Daniel A | Debridement method, device and kit |
US8673398B2 (en) * | 2006-02-23 | 2014-03-18 | Meadwestvaco Corporation | Method for treating a substrate |
WO2008051749A2 (en) | 2006-10-23 | 2008-05-02 | C. R. Bard, Inc. | Breast marker |
EP2109409B1 (en) | 2006-12-12 | 2018-09-05 | C.R.Bard, Inc. | Multiple imaging mode tissue marker |
EP2101670B1 (en) | 2006-12-18 | 2013-07-31 | C.R.Bard, Inc. | Biopsy marker with in situ-generated imaging properties |
WO2009099767A2 (en) | 2008-01-31 | 2009-08-13 | C.R. Bard, Inc. | Biopsy tissue marker |
AU2009240441B2 (en) * | 2008-04-25 | 2014-08-21 | Baxter International Inc. | Medical devices for delivering fluids during surgery and methods for their use |
US9327061B2 (en) | 2008-09-23 | 2016-05-03 | Senorx, Inc. | Porous bioabsorbable implant |
US9642658B2 (en) | 2008-10-15 | 2017-05-09 | Orthoclip Llc | Device and method for delivery of therapeutic agents via internal implants |
EP4215147A3 (en) | 2008-12-30 | 2023-10-18 | C. R. Bard, Inc. | Marker delivery device for tissue marker placement |
US9198987B2 (en) | 2010-06-25 | 2015-12-01 | Kci Licensing, Inc. | Systems and methods for imaging sinuses |
US9765380B2 (en) | 2010-12-08 | 2017-09-19 | Expression Pathology, Inc. | Truncated HER2 SRM/MRM assay |
US11883246B2 (en) * | 2012-11-21 | 2024-01-30 | Trustees Of Boston University | Tissue markers and uses thereof |
USD716451S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715942S1 (en) | 2013-09-24 | 2014-10-21 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD716450S1 (en) | 2013-09-24 | 2014-10-28 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
USD715442S1 (en) | 2013-09-24 | 2014-10-14 | C. R. Bard, Inc. | Tissue marker for intracorporeal site identification |
US10874921B2 (en) * | 2014-02-20 | 2020-12-29 | Parsons Xtreme Golf, LLC | Golf club heads and methods to manufacture golf club heads |
US11227427B2 (en) | 2014-08-11 | 2022-01-18 | Covidien Lp | Treatment procedure planning system and method |
US9909999B2 (en) | 2015-03-27 | 2018-03-06 | Delavan Inc. | Systems and methods for radiographic inspection |
US10071181B1 (en) | 2015-04-17 | 2018-09-11 | Teleflex Innovations S.À.R.L. | Resorbable embolization spheres |
US20190247638A1 (en) * | 2018-02-13 | 2019-08-15 | Kieran P. Murphy | Delivery system for delivering a drug depot to a target site under image guidance and methods and uses of same |
Family Cites Families (171)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2899362A (en) | 1959-08-11 | Hemostatic sponges and method of | ||
US451094A (en) * | 1891-04-28 | Sectional steam-generator | ||
US581235A (en) | 1897-04-20 | Island | ||
US1578517A (en) | 1924-12-23 | 1926-03-30 | George N Hein | Valve piston and barrel construction for hypodermic syringes |
US2086580A (en) | 1935-06-24 | 1937-07-13 | Myron C Shirley | Applicator |
US2465357A (en) | 1944-08-14 | 1949-03-29 | Upjohn Co | Therapeutic sponge and method of making |
US2370319A (en) | 1944-11-07 | 1945-02-27 | Dohner & Lippincott | Paper perforator |
US2492458A (en) | 1944-12-08 | 1949-12-27 | Jr Edgar A Bering | Fibrin foam |
US2507244A (en) | 1947-04-14 | 1950-05-09 | Upjohn Co | Surgical gelatin dusting powder and process for preparing same |
CH264752A (en) | 1947-06-03 | 1949-10-31 | Hoffmann La Roche | Process for the manufacture of carriers for pharmaceuticals. |
US2597011A (en) | 1950-07-28 | 1952-05-20 | Us Agriculture | Preparation of starch sponge |
US2680442A (en) | 1952-04-04 | 1954-06-08 | Frank L Linzmayer | Disposable suppository casing |
US2814294A (en) | 1953-04-17 | 1957-11-26 | Becton Dickinson Co | Unit for and method of inhibiting and controlling bleeding tendencies |
US2874776A (en) | 1954-06-07 | 1959-02-24 | Royal Mcbee Corp | Punch and die mechanism |
US2824092A (en) | 1955-01-04 | 1958-02-18 | Robert E Thompson | Process of preparation of a gelatincarboxymethyl cellulose complex |
US2761446A (en) | 1955-03-30 | 1956-09-04 | Chemical Specialties Co Inc | Implanter and cartridge |
GB858477A (en) | 1959-07-16 | 1961-01-11 | Yat Chuen Yuen | Improvements in or relating to drinking straws |
US3157524A (en) | 1960-10-25 | 1964-11-17 | Ethicon Inc | Preparation of collagen sponge |
US3358689A (en) | 1964-06-09 | 1967-12-19 | Roehr Products Company Inc | Integral lancet and package |
US3411505A (en) | 1965-12-15 | 1968-11-19 | Paul D. Nobis | Device for interrupting arterial flow |
US3703174A (en) | 1970-07-14 | 1972-11-21 | Medidyne Corp | Method and apparatus for catheter injection |
US3724465A (en) | 1971-07-22 | 1973-04-03 | Kimberly Clark Co | Tampon coated with insertion aid and method for coating |
US3736939A (en) | 1972-01-07 | 1973-06-05 | Kendall & Co | Balloon catheter with soluble tip |
US3874388A (en) | 1973-02-12 | 1975-04-01 | Ochsner Med Found Alton | Shunt defect closure system |
US4000741A (en) | 1975-11-03 | 1977-01-04 | The Kendall Company | Syringe assembly |
US4098728A (en) | 1976-01-02 | 1978-07-04 | Solomon Rosenblatt | Medical surgical sponge and method of making same |
SE7608618L (en) | 1976-07-30 | 1978-02-01 | Medline Ab | CLOSURE OF CHANNELS |
SU782814A1 (en) | 1977-01-18 | 1980-11-30 | За витель | Prosthesis for closing defect in heart tissues |
US4218155A (en) | 1978-02-10 | 1980-08-19 | Etablissements Armor, S.A. | Stick for applying a liquid |
US4588395A (en) | 1978-03-10 | 1986-05-13 | Lemelson Jerome H | Catheter and method |
US4900303A (en) | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
US4238480A (en) | 1978-05-19 | 1980-12-09 | Sawyer Philip Nicholas | Method for preparing an improved hemostatic agent and method of employing the same |
US4404970A (en) | 1978-05-19 | 1983-09-20 | Sawyer Philip Nicholas | Hemostatic article and methods for preparing and employing the same |
US4224945A (en) | 1978-08-30 | 1980-09-30 | Jonathan Cohen | Inflatable expansible surgical pressure dressing |
US4219026A (en) | 1978-09-15 | 1980-08-26 | The Kendall Company | Bladder hemostatic catheter |
US4211323A (en) | 1978-12-01 | 1980-07-08 | California Medical Developments, Inc. | Disposable diagnostic swab having a stored culture medium |
US4323072A (en) | 1980-01-18 | 1982-04-06 | Shiley, Incorporated | Cannula for a vein distention system |
US4340066A (en) | 1980-02-01 | 1982-07-20 | Sherwood Medical Industries Inc. | Medical device for collecting a body sample |
US4292972A (en) | 1980-07-09 | 1981-10-06 | E. R. Squibb & Sons, Inc. | Lyophilized hydrocolloio foam |
US4390018A (en) | 1980-09-15 | 1983-06-28 | Zukowski Henry J | Method for preventing loss of spinal fluid after spinal tap |
SU1088709A1 (en) | 1981-02-10 | 1984-04-30 | Институт Клинической И Экспериментальной Хирургии | Method of treatment of stomach fistula |
US4405314A (en) | 1982-04-19 | 1983-09-20 | Cook Incorporated | Apparatus and method for catheterization permitting use of a smaller gage needle |
NZ205033A (en) | 1982-08-12 | 1986-07-11 | Univ Alabama | Dispensing syringe with longitudinal slits in barrel |
EP0135334A1 (en) | 1983-08-13 | 1985-03-27 | Arthur Morris | Fountain |
US4573576A (en) | 1983-10-27 | 1986-03-04 | Krol Thomas C | Percutaneous gastrostomy kit |
US4515637A (en) | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
US4619913A (en) | 1984-05-29 | 1986-10-28 | Matrix Pharmaceuticals, Inc. | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
US4619261A (en) | 1984-08-09 | 1986-10-28 | Frederico Guerriero | Hydrostatic pressure device for bleeding control through an inflatable, stitchable and retrievable balloon-net system |
JPS6144825A (en) * | 1984-08-09 | 1986-03-04 | Unitika Ltd | Hemostatic agent |
US4573573A (en) * | 1985-01-02 | 1986-03-04 | Lori Favaro | Protective covering for portable audio devices |
US4587969A (en) | 1985-01-28 | 1986-05-13 | Rolando Gillis | Support assembly for a blood vessel or like organ |
US4869143A (en) | 1985-06-11 | 1989-09-26 | Merrick Industries, Inc. | Card file punch |
US4708718A (en) | 1985-07-02 | 1987-11-24 | Target Therapeutics | Hyperthermic treatment of tumors |
US4644649A (en) | 1985-09-26 | 1987-02-24 | Seaman Roy C | Apparatus for trimming reeds of musical instruments |
JPS62236560A (en) | 1986-04-09 | 1987-10-16 | テルモ株式会社 | Catheter for repairing blood vessel |
US4699616A (en) | 1986-06-13 | 1987-10-13 | Hollister Incorporated | Catheter retention device and method |
US4852568A (en) | 1987-02-17 | 1989-08-01 | Kensey Nash Corporation | Method and apparatus for sealing an opening in tissue of a living being |
US4744364A (en) | 1987-02-17 | 1988-05-17 | Intravascular Surgical Instruments, Inc. | Device for sealing percutaneous puncture in a vessel |
US4890612A (en) | 1987-02-17 | 1990-01-02 | Kensey Nash Corporation | Device for sealing percutaneous puncture in a vessel |
US4839204A (en) | 1987-05-19 | 1989-06-13 | Yazaki Kakoh Co., Ltd. | Resin coated metal pipe having a plane surface for a lightweight structure |
ES2086291T3 (en) | 1987-05-26 | 1996-07-01 | Sumitomo Pharma | DEVICE FOR THE ADMINISTRATION OF SOLID PREPARATIONS. |
US4829994A (en) | 1987-05-27 | 1989-05-16 | Kurth Paul A | Femoral compression device for post-catheterization hemostasis |
US4836204A (en) | 1987-07-06 | 1989-06-06 | Landymore Roderick W | Method for effecting closure of a perforation in the septum of the heart |
US4850960A (en) | 1987-07-08 | 1989-07-25 | Joseph Grayzel | Diagonally tapered, bevelled tip introducing catheter and sheath and method for insertion |
US4790819A (en) | 1987-08-24 | 1988-12-13 | American Cyanamid Company | Fibrin clot delivery device and method |
US5129889A (en) | 1987-11-03 | 1992-07-14 | Hahn John L | Synthetic absorbable epidural catheter |
US4936835A (en) | 1988-05-26 | 1990-06-26 | Haaga John R | Medical needle with bioabsorbable tip |
US5195988A (en) | 1988-05-26 | 1993-03-23 | Haaga John R | Medical needle with removable sheath |
US5254105A (en) | 1988-05-26 | 1993-10-19 | Haaga John R | Sheath for wound closure caused by a medical tubular device |
US5080655A (en) | 1988-05-26 | 1992-01-14 | Haaga John R | Medical biopsy needle |
US5053046A (en) | 1988-08-22 | 1991-10-01 | Woodrow W. Janese | Dural sealing needle and method of use |
US4929246A (en) | 1988-10-27 | 1990-05-29 | C. R. Bard, Inc. | Method for closing and sealing an artery after removing a catheter |
FR2641692A1 (en) | 1989-01-17 | 1990-07-20 | Nippon Zeon Co | Plug for closing an opening for a medical application, and device for the closure plug making use thereof |
US5007895A (en) | 1989-04-05 | 1991-04-16 | Burnett George S | Wound packing instrument |
US5219899A (en) | 1989-04-22 | 1993-06-15 | Degussa Aktiengesellschaft | Pasty dental material which is an organopolysilane filler combined with a polymerizable bonding agent |
US4973312A (en) | 1989-05-26 | 1990-11-27 | Andrew Daniel E | Method and system for inserting spinal catheters |
US5620461A (en) * | 1989-05-29 | 1997-04-15 | Muijs Van De Moer; Wouter M. | Sealing device |
DE3922406C1 (en) | 1989-07-07 | 1990-10-11 | B. Braun Melsungen Ag, 3508 Melsungen, De | |
US5232453A (en) | 1989-07-14 | 1993-08-03 | E. R. Squibb & Sons, Inc. | Catheter holder |
GB8916781D0 (en) | 1989-07-21 | 1989-09-06 | Nycomed As | Compositions |
US5049138A (en) | 1989-11-13 | 1991-09-17 | Boston Scientific Corporation | Catheter with dissolvable tip |
US5061274A (en) | 1989-12-04 | 1991-10-29 | Kensey Nash Corporation | Plug device for sealing openings and method of use |
US5021059A (en) | 1990-05-07 | 1991-06-04 | Kensey Nash Corporation | Plug device with pulley for sealing punctures in tissue and methods of use |
US5299581A (en) | 1990-07-05 | 1994-04-05 | Donnell John T | Intravaginal device |
US5192290A (en) | 1990-08-29 | 1993-03-09 | Applied Medical Resources, Inc. | Embolectomy catheter |
DE476178T1 (en) | 1990-09-21 | 1992-07-23 | Bioplex Medical B.V., Vaals | DEVICE FOR THE APPLICATION OF ANTI-BLOODING FABRIC ON PERFORATED BLOOD VESSELS. |
US5391183A (en) | 1990-09-21 | 1995-02-21 | Datascope Investment Corp | Device and method sealing puncture wounds |
US5192300A (en) | 1990-10-01 | 1993-03-09 | Quinton Instrument Company | Insertion assembly and method of inserting a vessel plug into the body of a patient |
US5108421A (en) | 1990-10-01 | 1992-04-28 | Quinton Instrument Company | Insertion assembly and method of inserting a vessel plug into the body of a patient |
US5167624A (en) | 1990-11-09 | 1992-12-01 | Catheter Research, Inc. | Embolus delivery system and method |
US5366480A (en) | 1990-12-24 | 1994-11-22 | American Cyanamid Company | Synthetic elastomeric buttressing pledget |
US5419765A (en) | 1990-12-27 | 1995-05-30 | Novoste Corporation | Wound treating device and method for treating wounds |
US5221259A (en) | 1990-12-27 | 1993-06-22 | Novoste Corporation | Wound treating device and method of using same |
US5310407A (en) | 1991-06-17 | 1994-05-10 | Datascope Investment Corp. | Laparoscopic hemostat delivery system and method for using said system |
CA2078530A1 (en) | 1991-09-23 | 1993-03-24 | Jay Erlebacher | Percutaneous arterial puncture seal device and insertion tool therefore |
JP3356447B2 (en) * | 1991-10-16 | 2002-12-16 | テルモ株式会社 | Vascular lesion embolic material composed of dried polymer gel |
US5676689A (en) * | 1991-11-08 | 1997-10-14 | Kensey Nash Corporation | Hemostatic puncture closure system including vessel location device and method of use |
US5282827A (en) * | 1991-11-08 | 1994-02-01 | Kensey Nash Corporation | Hemostatic puncture closure system and method of use |
US5163904A (en) | 1991-11-12 | 1992-11-17 | Merit Medical Systems, Inc. | Syringe apparatus with attached pressure gauge |
US5433725A (en) * | 1991-12-13 | 1995-07-18 | Unisurge, Inc. | Hand-held surgical device and tools for use therewith, assembly and method |
US6056768A (en) * | 1992-01-07 | 2000-05-02 | Cates; Christopher U. | Blood vessel sealing system |
IL105529A0 (en) * | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
US5326350A (en) * | 1992-05-11 | 1994-07-05 | Li Shu Tung | Soft tissue closure systems |
US5220926A (en) | 1992-07-13 | 1993-06-22 | Jones George T | Finger mounted core biopsy guide |
US5413571A (en) | 1992-07-16 | 1995-05-09 | Sherwood Medical Company | Device for sealing hemostatic incisions |
US5514379A (en) * | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5334216A (en) | 1992-12-10 | 1994-08-02 | Howmedica Inc. | Hemostatic plug |
US5417699A (en) * | 1992-12-10 | 1995-05-23 | Perclose Incorporated | Device and method for the percutaneous suturing of a vascular puncture site |
AU674546B2 (en) * | 1992-12-15 | 1997-01-02 | Johnson & Johnson Consumer Products, Inc. | Hydrogel laminate, bandages and composites and methods for forming the same |
CZ191695A3 (en) | 1993-01-25 | 1996-05-15 | Sonus Pharma Inc | Biologically compatible contrast agent, process of its preparation and representation method by ultrasound |
US5370656A (en) | 1993-02-26 | 1994-12-06 | Merocel Corporation | Throat pack |
US5320639A (en) | 1993-03-12 | 1994-06-14 | Meadox Medicals, Inc. | Vascular plug delivery system |
US5322515A (en) | 1993-03-15 | 1994-06-21 | Abbott Laboratories | Luer adapter assembly for emergency syringe |
US5342388A (en) | 1993-03-25 | 1994-08-30 | Sonia Toller | Method and apparatus for sealing luminal tissue |
US5388588A (en) | 1993-05-04 | 1995-02-14 | Nabai; Hossein | Biopsy wound closure device and method |
US5383896A (en) | 1993-05-25 | 1995-01-24 | Gershony; Gary | Vascular sealing device |
DE59400518D1 (en) * | 1993-06-16 | 1996-09-26 | White Spot Ag | DEVICE FOR PUTTING FIBRINE ADHESIVE INTO A STITCH CHANNEL |
US5325857A (en) | 1993-07-09 | 1994-07-05 | Hossein Nabai | Skin biopsy device and method |
US5352211A (en) | 1993-07-11 | 1994-10-04 | Louisville Laboratories | External stability device |
US5486195A (en) | 1993-07-26 | 1996-01-23 | Myers; Gene | Method and apparatus for arteriotomy closure |
US5431639A (en) | 1993-08-12 | 1995-07-11 | Boston Scientific Corporation | Treating wounds caused by medical procedures |
US5383899A (en) | 1993-09-28 | 1995-01-24 | Hammerslag; Julius G. | Method of using a surface opening adhesive sealer |
US5653730A (en) | 1993-09-28 | 1997-08-05 | Hemodynamics, Inc. | Surface opening adhesive sealer |
ES2227542T3 (en) * | 1993-11-03 | 2005-04-01 | Clarion Pharmaceuticals, Inc. | HEMOSTATIC PATCH. |
US5507279A (en) * | 1993-11-30 | 1996-04-16 | Fortune; John B. | Retrograde endotracheal intubation kit |
US5649547A (en) | 1994-03-24 | 1997-07-22 | Biopsys Medical, Inc. | Methods and devices for automated biopsy and collection of soft tissue |
US5526822A (en) | 1994-03-24 | 1996-06-18 | Biopsys Medical, Inc. | Method and apparatus for automated biopsy and collection of soft tissue |
US5385550A (en) | 1994-03-29 | 1995-01-31 | Su; Chan-Ho | Needle protective means for prevention against stab and virus infection |
US5545178A (en) | 1994-04-29 | 1996-08-13 | Kensey Nash Corporation | System for closing a percutaneous puncture formed by a trocar to prevent tissue at the puncture from herniating |
US5522850A (en) | 1994-06-23 | 1996-06-04 | Incontrol, Inc. | Defibrillation and method for cardioverting a heart and storing related activity data |
EP0776230B1 (en) * | 1994-08-17 | 2001-10-24 | Boston Scientific Corporation | Implant and device for inserting the implant |
US5931165A (en) * | 1994-09-06 | 1999-08-03 | Fusion Medical Technologies, Inc. | Films having improved characteristics and methods for their preparation and use |
US5490736A (en) * | 1994-09-08 | 1996-02-13 | Habley Medical Technology Corporation | Stylus applicator for a rehydrated multi-constituent medication |
WO1996008208A1 (en) | 1994-09-16 | 1996-03-21 | Biopsys Medical, Inc. | Methods and devices for defining and marking tissue |
US5624402A (en) * | 1994-12-12 | 1997-04-29 | Becton, Dickinson And Company | Syringe tip cap |
JPH10512470A (en) * | 1995-01-18 | 1998-12-02 | メドケム プロダクツ,インコーポレーテッド | Apparatus and method for applying a hemostatic agent to tissue |
US6183497B1 (en) * | 1998-05-01 | 2001-02-06 | Sub-Q, Inc. | Absorbable sponge with contrasting agent |
US6162192A (en) * | 1998-05-01 | 2000-12-19 | Sub Q, Inc. | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
US5645566A (en) | 1995-09-15 | 1997-07-08 | Sub Q Inc. | Apparatus and method for percutaneous sealing of blood vessel punctures |
US6071300A (en) * | 1995-09-15 | 2000-06-06 | Sub-Q Inc. | Apparatus and method for percutaneous sealing of blood vessel punctures |
US6071301A (en) * | 1998-05-01 | 2000-06-06 | Sub Q., Inc. | Device and method for facilitating hemostasis of a biopsy tract |
US5769086A (en) | 1995-12-06 | 1998-06-23 | Biopsys Medical, Inc. | Control system and method for automated biopsy device |
US5800389A (en) * | 1996-02-09 | 1998-09-01 | Emx, Inc. | Biopsy device |
US5601207A (en) * | 1996-03-13 | 1997-02-11 | Paczonay; Joseph R. | Bite valve having a plurality of slits |
US5827218A (en) * | 1996-04-18 | 1998-10-27 | Stryker Corporation | Surgical suction pool tip |
US5858008A (en) * | 1997-04-22 | 1999-01-12 | Becton, Dickinson And Company | Cannula sealing shield assembly |
US5902310A (en) | 1996-08-12 | 1999-05-11 | Ethicon Endo-Surgery, Inc. | Apparatus and method for marking tissue |
US6063061A (en) * | 1996-08-27 | 2000-05-16 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6066325A (en) * | 1996-08-27 | 2000-05-23 | Fusion Medical Technologies, Inc. | Fragmented polymeric compositions and methods for their use |
US6706690B2 (en) * | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
US5810806A (en) | 1996-08-29 | 1998-09-22 | Ethicon Endo-Surgery | Methods and devices for collection of soft tissue |
US5681279A (en) | 1996-11-04 | 1997-10-28 | Roper; David H. | Pill dispensing syringe |
US5782861A (en) * | 1996-12-23 | 1998-07-21 | Sub Q Inc. | Percutaneous hemostasis device |
US6197327B1 (en) * | 1997-06-11 | 2001-03-06 | Umd, Inc. | Device and method for treatment of dysmenorrhea |
US5868762A (en) * | 1997-09-25 | 1999-02-09 | Sub-Q, Inc. | Percutaneous hemostatic suturing device and method |
US6033427A (en) * | 1998-01-07 | 2000-03-07 | Lee; Benjamin I. | Method and device for percutaneous sealing of internal puncture sites |
US6161034A (en) * | 1999-02-02 | 2000-12-12 | Senorx, Inc. | Methods and chemical preparations for time-limited marking of biopsy sites |
US6200328B1 (en) * | 1998-05-01 | 2001-03-13 | Sub Q, Incorporated | Device and method for facilitating hemostasis of a biopsy tract |
US6315753B1 (en) * | 1998-05-01 | 2001-11-13 | Sub-Q, Inc. | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
US20010045575A1 (en) * | 1998-05-01 | 2001-11-29 | Mark Ashby | Device and method for facilitating hemostasis of a biopsy tract |
US6126675A (en) * | 1999-01-11 | 2000-10-03 | Ethicon, Inc. | Bioabsorbable device and method for sealing vascular punctures |
EP1156741B1 (en) * | 1999-02-10 | 2010-12-22 | Sub-Q, Inc. | Device for facilitating hemostasis of a biopsy tract |
US6984219B2 (en) * | 1999-09-23 | 2006-01-10 | Mark Ashby | Depth and puncture control for blood vessel hemostasis system |
US6547806B1 (en) * | 2000-02-04 | 2003-04-15 | Ni Ding | Vascular sealing device and method of use |
EP1289718A1 (en) * | 2000-04-28 | 2003-03-12 | Sub-Q, Inc. | Easy cutter |
US6540735B1 (en) * | 2000-05-12 | 2003-04-01 | Sub-Q, Inc. | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge |
US6503222B2 (en) * | 2000-09-28 | 2003-01-07 | Pfizer Inc | Oral dosage dispenser |
US8187625B2 (en) * | 2001-03-12 | 2012-05-29 | Boston Scientific Scimed, Inc. | Cross-linked gelatin composition comprising a wetting agent |
US7008440B2 (en) * | 2001-11-08 | 2006-03-07 | Sub-Q, Inc. | System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
US6863680B2 (en) * | 2001-11-08 | 2005-03-08 | Sub-Q, Inc. | System and method for delivering hemostasis promoting material to a blood vessel puncture site by fluid pressure |
US7025748B2 (en) * | 2001-11-08 | 2006-04-11 | Boston Scientific Scimed, Inc. | Sheath based blood vessel puncture locator and depth indicator |
-
1999
- 1999-06-17 US US09/335,452 patent/US6183497B1/en not_active Expired - Lifetime
-
2000
- 2000-06-16 AU AU58772/00A patent/AU5877200A/en not_active Abandoned
- 2000-06-16 EP EP00944716A patent/EP1191884A1/en not_active Withdrawn
- 2000-06-16 WO PCT/US2000/016775 patent/WO2000078228A1/en not_active Application Discontinuation
- 2000-06-16 CA CA002371841A patent/CA2371841A1/en not_active Abandoned
- 2000-06-16 JP JP2001504297A patent/JP4460203B2/en not_active Expired - Fee Related
-
2001
- 2001-09-27 US US09/966,611 patent/US20020038133A1/en not_active Abandoned
-
2004
- 2004-10-29 US US10/978,321 patent/US7618567B2/en not_active Expired - Fee Related
-
2009
- 2009-10-13 US US12/578,088 patent/US20100029908A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/776,952 patent/US20130172737A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020038133A1 (en) | 2002-03-28 |
WO2000078228A9 (en) | 2002-09-26 |
CA2371841A1 (en) | 2000-12-28 |
JP2003502099A (en) | 2003-01-21 |
US7618567B2 (en) | 2009-11-17 |
US20100029908A1 (en) | 2010-02-04 |
AU5877200A (en) | 2001-01-09 |
US20050059080A1 (en) | 2005-03-17 |
WO2000078228A1 (en) | 2000-12-28 |
US6183497B1 (en) | 2001-02-06 |
EP1191884A1 (en) | 2002-04-03 |
JP4460203B2 (en) | 2010-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7618567B2 (en) | Absorbable sponge with contrasting agent | |
US6440151B1 (en) | Device and method for facilitating hemostasis of a biopsy tract | |
US8050741B2 (en) | Device and method for facilitating hemostasis of a biopsy tract | |
US6447534B2 (en) | Device and method for facilitating hemostasis of a biopsy tract | |
US6540735B1 (en) | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge | |
AU748773B2 (en) | System and method for facilitating hemostasis of blood vessel punctures with absorbable sponge | |
WO2002074214A1 (en) | Method of hydrating a sponge material for delivery to a body | |
AU7715600A (en) | Device and method for determining a depth of an incision | |
AU2005202005A1 (en) | Absorbable sponge with contrasting agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |